Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexketamine and dexmedetomidine for lung protection during one-lung ventilation in COPD patients
ChiCTR2200062621Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Fujian Medical University
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of esketamine and dexmedetomidine in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by The Second Affiliated Hospital of Fujian Medical University. Primary endpoints: Peak airway pressure, Plateau airway pressure and 8 more. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
esketaminedexmedetomidine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR2200062621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062621.